### CCR Translations

4419  

TP53 Mutations and Lung Cancer: Not All Mutations Are Created Equal  
Ramaswamy Govindan and Jason Weber  
*See related article, p. 4647*

4422  

“Companion Diagnostics”: Has Their Time Come and Gone?  
Fred R. Hirsch, Paul A. Bunn Jr, and Roy S. Herbst  
*See related article, p. 4488*

### CCR New Strategies

4425  

New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs  
Juliane M. Jürgensmeier, Joseph P. Eder, and Roy S. Herbst

### CCR Perspectives in Drug Approval

4436  

FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer  

### Molecular Pathways

4442  

Molecular Pathways: Targeting ETS Gene Fusions in Cancer  
Felix Y. Feng, J. Chad Brenner, Maha Hussain, and Arul M. Chinnaiyan

### CANCER THERAPY: CLINICAL

4449  

Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)  

4459  

p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8⁺ T-cell Responses  
Nicola R. Hardwick, Mary Carroll, Teodora Kaltcheva, Dajun Qian, Dean Lim, Lucille Leong, Peigu Chu, Joseph Kim, Joseph Chao, Marwan Fakih, Yun Yen, Jonathan Espeńchies, Joshua D.L. Ellenhorn, Don J. Diamond, and Vincent Chung

4471  

Phase I Safety and Pharmacodynamic of Inecalcitol, a Novel VDR Agonist with Docetaxel in Metastatic Castration-Resistant Prostate Cancer Patients  
Jacques Medioni, Gail Deplanque, Jean-Marc Ferrero, Tristan Maurina, Jean-Michel P. Rodier, Eric Raymond, Jorge Allyon, Gerard Maruani, Pascal Houllier, Sarah Mackenzie, Stephanie Renaux, Jean-François Dufour-Lamartinie, Reza Elaidi, Celine Lerest, and Stephane Oudard

### PERSONALIZED MEDICINE AND IMAGING

4478  

Association of EGFR Expression Level and Cetuximab Activity in Patient-Derived Xenograft Models of Human Non–Small Cell Lung Cancer  
Christiane Amendt, Eike Staub, Manja Friese-Hamim, Stephan Störkel, and Christopher Stroh

4488  

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit  
*See related commentary, p. 4422*
4499  Let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy
Zenia Saridaki, Joanne B. Weidhaas, Heinz-Josef Lenz, Pierre Laurent-Puig, Bart Jacobs, Jef De Schutter, Wendy De Roock, David W. Salzman, Wu Zhang, Dongyun Yang, Camilla Pilati, Olivier Bouché, Hubert Piessevaux, and Sabine Tejpar

4511  FcyRIIA and FcyRIIIB Polymorphisms and Cetuximab Benefit in the Microscopic Disease Fracture Line of the Metastasis-Forming Cell Line 8226
Francesco Sclafani, David Gonzalez de Castro, David Cunningham, Sanna Hulkki Wilson, Clare Peckitt, Jaime Capdevila, Bengt Glimelius, Susana Roselló Keränen, Andrew Motherspoon, Gina Brown, Diana Tait, Ruwaida Begum, Janet Thomas, Jacqueline Oates, and Ian Chau

4520  Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts

4532  Noninvasive Detection of Glutamate Predicts Survival in Pediatric Medulloblastoma
Martin Wilson, Simrandip K. Gill, Lesley MacPherson, Martin English, Theodoros N. Arvanitis, and Andrew C. Peet

4540  Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of IGH

4549  The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer
Alison Backen, Andrew C. Renehan, Andrew R. Clamp, Carlo Berzuini, Cong Zhou, Amit Oza, Selina Bannoo, Stefan J. Scherer, Rosamonde E. Banks, Caroline Dive, and Gordon C. Jayson

4559  Functional Genetic Approach Identifies MET, HER3, IGF1R, INSR Pathways as Determinants of Laptzibin Unresponsiveness in HER2-Positive Gastric Cancer
Zhe Zhang, Jiping Wang, Dongmei Ji, Heinz-Josef Lenz, Pierre Laurent-Puig, Bart Jacobs, Jef De Schutter, Wendy De Roock, David W. Salzman, Wu Zhang, Dongyun Yang, Camilla Pilati, Olivier Bouché, Hubert Piessevaux, and Sabine Tejpar

4574  SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
Jutta Deckert, Marie-Cécile Wetzel, Laura M. Bartle, Anna Sclafani, Viktoras Frismantas, Chintanu Sarmah, François Vallée, Qing Zhou-Liu, Paul Ferrari, Stéphanie Pouzieux, Charlotte Lahoute, Charles Dumontet, Adriana Plesa, Mariele Chiron, Pascale Lejeune, Thomas Chittenden, Peter U. Park, and Véronique Blanc

4584  Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth
Savita Sankar, Emily R. Theisen, Jared Bearss, Timothy Mulvihill, Laura M. Hoffman, Venkatathswamy Soma, Mary C. Beckerle, Sunil Sharma, and Stephen L. Lessnick
4625 Expression of Androgen and Estrogen Signaling Components and Stem Cell Markers to Predict Cancer Progression and Cancer-Specific Survival in Patients with Metastatic Prostate Cancer
Tetsuya Fujimura, Satoru Takahashi, Tomohiko Urano, Kenichi Takayama, Toru Sugihara, Daisuke Obinata, Yuta Yamada, Jimpiei Kumagai, Haruki Kume, Yasuyoshi Ouchi, Satoshi Inoue, and Yukio Homma

4636 miR-409-3p/-5p Promotes Tumorigenesis, Epithelial-to-Mesenchymal Transition, and Bone Metastasis of Human Prostate Cancer

4647 Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer
Miguel A. Molina-Vila, Jordi Bertran-Alamillo, Amaya Gascó, Clara Mayo-de-las-Casas, Marí a Sánchez-Ronco, Laia Pujantell-Pastor, Laura Bonanno, Adolfo G. Favaretto, Andrés F. Cordona, Alain Vergnenègre, Margarita Majem, Bartomeu Massuti, Teresa Morán, Enric Carcereny, Santiago Viteri, and Rafael Rosell
See related commentary, p. 4419

4660 An Integrative Analysis of the Tumorigenic Role of TAZ in Human Non–Small Cell Lung Cancer

4673 To “Grow” or “Go”: TMEM16A Expression as a Switch between Tumor Growth and Metastasis in SCCHN
Daniel J. Shiwariski, Chunbo Shao, Anke Bill, Jean Kim, Dong Xiao, Carol A. Bertrand, Raja S. Seethala, Daisuke Sano, Jeffery N. Myers, Patrick Ha, Jennifer Grandis, L. Alex Gaither, Manojkumar A. Pathenveedu, and Umamaheswar Duvvuri

4689 TMEFF2 Deregulation Contributes to Gastric Carcinogenesis and Indicates Poor Survival Outcome
Tiantian Sun, Wan Du, Hua Xiong, Yanan Yu, Yurong Weng, Linlin Ren, Huijun Zhao, Yingchao Wang, Yingxuan Chen, Jie Xu, Yongbing Xiang, Wenxin Qin, Weibiao Cao, Weiping Zou, Haoyan Chen, Jie Hong, and Jing-Yuan Fang

4705 Decreased Expression of miR216a Contributes to Non–Small-Cell Lung Cancer Progression
Ren-Tao Wang, Meng Xu, Cheng-Xiong Xu, Zhi-Gang Song, and Hua Jin

4717 GSK-3β–Regulated N-Acetyltransferase 10 Is Involved in Colorectal Cancer Invasion
Hong Zhang, Wei Hou, Hua-Li Wang, Hai-Jing Liu, Xin-Ying Jia, Xing-Zheng Zheng, Yong-Xin Zou, Xin Li, Lin Hou, Michael A. McNutt, and Bo Zhang
ABOUT THE COVER

The cover shows the crystal structure of the SAR650984-Fab in complex with human CD38 resolved at 1.53 Å resolution. A close-up view of the epitope highlights the interface between human CD38 and SAR650984-Fab, which involves mainly antibody heavy chain CDR loop H3 (yellow) and light chain CDR loops L1, L2 and L3 (green). For details, see the article by Deckert and colleagues on page 4574 of this issue.